JP2018521959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521959A5 JP2018521959A5 JP2017556585A JP2017556585A JP2018521959A5 JP 2018521959 A5 JP2018521959 A5 JP 2018521959A5 JP 2017556585 A JP2017556585 A JP 2017556585A JP 2017556585 A JP2017556585 A JP 2017556585A JP 2018521959 A5 JP2018521959 A5 JP 2018521959A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- btla
- composition
- item
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 37
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 9
- 229940122494 BTLA agonist Drugs 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 claims description 6
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 108010008165 Etanercept Proteins 0.000 claims description 4
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 4
- 102100033461 Interleukin-17A Human genes 0.000 claims description 4
- 102000000704 Interleukin-7 Human genes 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 102000000585 Interleukin-9 Human genes 0.000 claims description 4
- 108010002335 Interleukin-9 Proteins 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 229960004641 rituximab Drugs 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 102000013135 CD52 Antigen Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000014311 Cushing syndrome Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 102100023688 Eotaxin Human genes 0.000 claims description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 claims description 2
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 claims description 2
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims description 2
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims description 2
- 102100026720 Interferon beta Human genes 0.000 claims description 2
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 2
- 101710147309 Interferon epsilon Proteins 0.000 claims description 2
- 102100026688 Interferon epsilon Human genes 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims description 2
- 102000006992 Interferon-alpha Human genes 0.000 claims description 2
- 108090000467 Interferon-beta Proteins 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 102000003815 Interleukin-11 Human genes 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102100039064 Interleukin-3 Human genes 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102000000743 Interleukin-5 Human genes 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 241000966334 Simias Species 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims description 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims description 2
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 229960003697 abatacept Drugs 0.000 claims description 2
- 229940119059 actemra Drugs 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229960003115 certolizumab pegol Drugs 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 229940038717 copaxone Drugs 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002066 eicosanoids Chemical group 0.000 claims description 2
- 229940073621 enbrel Drugs 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 229960000556 fingolimod Drugs 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 229940048921 humira Drugs 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 2
- 229960005027 natalizumab Drugs 0.000 claims description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 229940038850 rebif Drugs 0.000 claims description 2
- 229940116176 remicade Drugs 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 229940068638 simponi Drugs 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 229960000331 teriflunomide Drugs 0.000 claims description 2
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims description 2
- 229960003989 tocilizumab Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 25
- SWZTYAVBMYWFGS-UHFFFAOYSA-N fingolimod hydrochloride Chemical compound Cl.CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 SWZTYAVBMYWFGS-UHFFFAOYSA-N 0.000 claims 2
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 241001254135 Gillenia Species 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022011710A JP2022044795A (ja) | 2015-04-29 | 2022-01-28 | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
| JP2024034837A JP2024056047A (ja) | 2015-04-29 | 2024-03-07 | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154484P | 2015-04-29 | 2015-04-29 | |
| US62/154,484 | 2015-04-29 | ||
| PCT/US2016/030138 WO2016176583A1 (en) | 2015-04-29 | 2016-04-29 | Modulation of immune response using btla agonist antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011710A Division JP2022044795A (ja) | 2015-04-29 | 2022-01-28 | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521959A JP2018521959A (ja) | 2018-08-09 |
| JP2018521959A5 true JP2018521959A5 (enExample) | 2019-05-30 |
Family
ID=57198828
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556585A Pending JP2018521959A (ja) | 2015-04-29 | 2016-04-29 | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
| JP2022011710A Pending JP2022044795A (ja) | 2015-04-29 | 2022-01-28 | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
| JP2024034837A Pending JP2024056047A (ja) | 2015-04-29 | 2024-03-07 | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011710A Pending JP2022044795A (ja) | 2015-04-29 | 2022-01-28 | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
| JP2024034837A Pending JP2024056047A (ja) | 2015-04-29 | 2024-03-07 | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11352428B2 (enExample) |
| EP (1) | EP3288587A4 (enExample) |
| JP (3) | JP2018521959A (enExample) |
| WO (1) | WO2016176583A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018521959A (ja) | 2015-04-29 | 2018-08-09 | サンフォード−バーナム メディカル リサーチ インスティテュート | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
| KR20240110000A (ko) | 2015-06-30 | 2024-07-12 | 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 | Btla 융합 단백질 작용제 및 이의 용도 |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| JOP20190261A1 (ar) * | 2017-05-19 | 2019-11-05 | Lilly Co Eli | أجسام مضادة لعامل مساعد لـ btla واستخداماتها |
| CN113603776B (zh) * | 2018-02-12 | 2022-10-21 | 原启生物科技(上海)有限责任公司 | Il17抗体及其应用 |
| GB201820554D0 (en) * | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| JP7596298B2 (ja) * | 2019-04-01 | 2024-12-09 | クリア・アイピー・ホールディングス・リミテッド・ライアビリティ・カンパニー | 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体 |
| GB202008860D0 (en) * | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024243594A1 (en) * | 2023-05-25 | 2024-11-28 | Anaptysbio, Inc. | Btla agonist for mudulation of dendritic cells |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE359297T1 (de) * | 2002-06-12 | 2007-05-15 | Applied Research Systems | Antagonisten für cxcr3-bindende cxc-chemokine |
| US8349320B2 (en) * | 2004-12-09 | 2013-01-08 | La Jolla Institute For Allergy And Immunology | Compositions and methods for modulating responses mediated or associated with BTLA activity |
| WO2010006071A1 (en) * | 2008-07-08 | 2010-01-14 | La Jolla Institute For Allergy And Immunology | Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use |
| AU2007278054B2 (en) * | 2006-07-24 | 2012-11-22 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation |
| EP2459594A1 (en) * | 2009-07-31 | 2012-06-06 | N.V. Organon | Fully human antibodies to btla |
| WO2014183885A1 (en) * | 2013-05-17 | 2014-11-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of the btla/hvem interaction for use in therapy |
| US10759863B2 (en) | 2013-09-05 | 2020-09-01 | Sanford Burnham Prebys Medical Discovery Institute | Modulation of γδ T cells |
| JP2018521959A (ja) | 2015-04-29 | 2018-08-09 | サンフォード−バーナム メディカル リサーチ インスティテュート | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
-
2016
- 2016-04-29 JP JP2017556585A patent/JP2018521959A/ja active Pending
- 2016-04-29 EP EP16787238.1A patent/EP3288587A4/en not_active Withdrawn
- 2016-04-29 WO PCT/US2016/030138 patent/WO2016176583A1/en not_active Ceased
- 2016-04-29 US US15/570,013 patent/US11352428B2/en active Active
-
2022
- 2022-01-28 JP JP2022011710A patent/JP2022044795A/ja active Pending
- 2022-05-16 US US17/745,459 patent/US20220380468A1/en not_active Abandoned
-
2024
- 2024-03-07 JP JP2024034837A patent/JP2024056047A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521959A5 (enExample) | ||
| Voge et al. | Monoclonal antibodies in multiple sclerosis: present and future | |
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| JP2020515247A5 (enExample) | ||
| JP2017531427A5 (enExample) | ||
| JP2019513725A5 (enExample) | ||
| US11939367B2 (en) | BTLA fusion protein agonists and uses thereof | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| JP2016507555A5 (enExample) | ||
| JP2018512170A5 (enExample) | ||
| US11352428B2 (en) | Modulation of immune response using BTLA agonist antibodies | |
| JP2014111644A5 (enExample) | ||
| CA2896548A1 (en) | Multivalent binding protein compositions | |
| JP2018508475A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| Jinesh | Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs | |
| JP2020501550A5 (enExample) | ||
| EP2948475A2 (en) | Methods and compositions for modulating an immune response | |
| JP2017537972A5 (enExample) | ||
| Guo et al. | Empowering therapeutic antibodies with IFN-α for cancer immunotherapy | |
| Arulanandam et al. | Derivation and preclinical characterization of CYT-303, a novel NKp46-NK cell engager targeting GPC3 | |
| Ciano-Petersen et al. | Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis | |
| RU2019104896A (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования | |
| Dawalibi et al. | Balancing the scales: the dual role of interleukins in bone metastatic microenvironments |